WuXi XDC
Shanghai, China (also: Wuxi, China; Singapore site in commissioning)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: WuXi XDC
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Shanghai, China (also: Wuxi, China; Singapore site in commissioning)
- Modalities
- ADC (Antibody-Drug Conjugate), Bioconjugates (XDC), mAb intermediates, Payload-linker synthesis, Drug substance (DS), Drug product (DP), Bispecific ADCs, RDC (Radioimmunoconjugates), AOC / DAC / APC
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About WuXi XDC
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesADC (Antibody-Drug Conjugate), Bioconjugates (XDC), mAb intermediates, Payload-linker synthesis, Drug substance (DS), Drug product (DP), Bispecific ADCs, RDC (Radioimmunoconjugates), AOC / DAC / APC
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (9 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (9 modalities)
Recent News 10 articles
Celltrion strengthens partnership with WuXi XDC to develop ADCs - koreabiomed.com
Profit growth outlook: Wuxi XDC (02268) further solidifies its position in the ADC CDMO market following the acquisition of TOT Biopharm. - Moomoo
WuXi XDC completes construction of Singapore bioconjugation site - BioProcess International
WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead - boerse.de
WuXi XDC Named the Winner of "Best CDMO" and "Best CRO" at 2025 World ADC Awards - PR Newswire
WuXi XDC Established as New CDMO - Genetic Engineering and Biotechnology News
WuXi XDC unveils GMP-certified facility in China - BioProcess International
WuXi Biologics breaks ground on microbial production plant in China - Fierce Pharma
WuXi XDC, Earendil Labs Partner to Accelerate the Development of ADCs - Contract Pharma
Chinese CDMO seeks to consolidate leadership in ADC space - The Pharma Letter
Represent this organization? Contact us to verify or update this profile.